BioSpace.com

Biotech and Pharmaceutical
News & Jobs
Search the Site
 
   
Biotechnology and Pharmaceutical Channel Medical Device and Diagnostics Channel Clinical Research Channel BioSpace Collaborative    Job Seekers:  Register | Login          Employers:  Register | Login  

NEWSLETTERS
Free Newsletters
Archive
My Subscriptions

NEWS
News by Subject
News by Disease
News by Date
PLoS
Search News
Post Your News
JoVE

CAREER NETWORK
Job Seeker Login
Most Recent Jobs
Browse Biotech Jobs
Search Jobs
Post Resume
Career Fairs
Career Resources
For Employers

HOTBEDS
Regional News
US & Canada
  Biotech Bay
  Biotech Beach
  Genetown
  Pharm Country
  BioCapital
  BioMidwest
  Bio NC
  BioForest
  Southern Pharm
  BioCanada East
  US Device
Europe
Asia

DIVERSITY

INVESTOR
Market Summary
News
IPOs

PROFILES
Company Profiles

START UPS
Companies
Events

INTELLIGENCE
Research Store

INDUSTRY EVENTS
Biotech Events
Post an Event
RESOURCES
Real Estate
Business Opportunities

 News | News By Subject | News by Disease News By Date | Search News
eNewsletter Signup
Miles
Km80.5

   

Riverside Partners Buys Dominion Diagnostics


12/20/2010 8:33:54 AM

Riverside Partners, a Boston-based private equity firm, is pleased to announce that it has made a majority equity investment in Dominion Diagnostics (”Dominion”), a leading laboratory services company focused on quantitative testing to support patient medication monitoring. The investment was completed in partnership with the founders and management of the business.

Founded in 1997, Dominion is a premier provider of comprehensive clinical quantitative urine drug testing, medication monitoring, and support services nationwide. For the past 13 years, Dominion has provided laboratory services to thousands of clients in a variety of medical specialties, including Addiction Treatment, Behavioral Health, Pain Medicine, Primary Care, Psychiatry and Hospital Systems.

“When we decided to bring on a financial partner for Dominion, we focused on finding a private equity firm with significant health care expertise as well as experience working with founder-owned companies. We are extremely excited about our partnership with Riverside Partners and believe that together we will continue to help clinicians and patients and improve clinical outcomes,” said Dr. Frank Fornari, Founder of Dominion Diagnostics.

“Dominion is one of the leading nationwide laboratories for pain management and addiction medicine and provides a critical service for health care professionals and patients,” said Philip Borden, a General Partner at Riverside Partners. ” Frank and the Dominion team have created a company with a strong scientific foundation, based on integrity, high quality and service, and a commitment to patient care and compliance. We are eager to support Dominion’s growth with additional capital and resources.”

About Dominion

Dominion Diagnostics is a premier provider of comprehensive clinical quantitative urine drug testing, medication monitoring, and support services nationwide. For over 13 years, Dominion has provided services to thousands of clients in a variety of medical specialties, including Addiction Treatment, Behavioral Health, Pain Medicine, Primary Care, Psychiatry and Hospital Systems. Dominion is supported by a world-class team that shares a commitment to clinical and operational excellence. For more information about Dominion, please visit www.dominiondiagnostics.com.

About Riverside Partners

Founded in 1989, Riverside Partners is a middle market private equity firm currently investing Riverside Partners Fund IV, L.P. The fund focuses on growth oriented companies primarily in the healthcare and technology industries. Riverside Partners is particularly experienced at partnering with founders, owners and management teams and it brings substantial domain expertise and operating experience to its portfolio companies. The partners at Riverside Partners have managed more than $500 million in investments in over 50 companies. The firm is currently focused on companies with revenues between $20 and $200 million and with $5-$25 million of EBITDA. For more information, please visit http://www.riversidepartners.com.


Read at BioSpace.com

   

ADD TO DEL.ICIO.US    ADD TO DIGG    ADD TO FURL    ADD TO STUMBLEUPON    ADD TO TECHNORATI FAVORITES